GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jul 23, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jul 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on July 23, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.
Key Players & Entities
- GSK plc (company) — The company making the share purchase.
- Merrill Lynch International (company) — The corporate stockbroker acting on behalf of GSK plc.
- July 2025 (date) — The period during which the transactions occurred.
FAQ
What was the specific date of the share purchase?
The filing states the purchase occurred during the month of July 2025, but a specific date within July is not provided in the excerpt.
How many ordinary shares did GSK plc purchase?
The filing indicates that a 'number' of ordinary shares were purchased, but the exact quantity is not specified in the provided text.
What was the total dollar amount of the share repurchase?
The filing does not disclose the total dollar amount spent on the share repurchase.
Who is GSK plc's corporate stockbroker for this transaction?
GSK plc is acting through its corporate stockbroker, Merrill Lynch International.
What is the par value of GSK plc's ordinary shares?
The ordinary shares are of 31¼ pence each.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 23, 2025 regarding GSK plc (GLAXF).